Key result
Oral long-term anticoagulation with coumarins in ESRD patients with atrial fibrillation lacks strong supporting data and carries increased risks of bleeding and cardiovascular calcification.
Why the study?
Does oral long-term anticoagulation provide safe and effective stroke prophylaxis in end-stage renal disease patients with atrial fibrillation?
Population
End-stage renal disease (ESRD) patients, particularly those with atrial fibrillation
Design
Review
Authors
Loading...
Caution advised against routine coumarin use for AF in ESRD; leaves open need for RCTs on safer options.
Does oral long-term anticoagulation provide safe and effective stroke prophylaxis in end-stage renal disease patients with atrial fibrillation?
The routine use of coumarins for stroke prophylaxis in ESRD patients with atrial fibrillation lacks strong evidence and carries significant risks of bleeding and calciphylaxis.
Krüger et al. (2012) conducted a review in End-stage renal disease (ESRD) with atrial fibrillation. Coumarins (vitamin K antagonists) was evaluated. Oral long-term anticoagulation with coumarins in ESRD patients with atrial fibrillation lacks strong supporting data and carries increased risks of bleeding and cardiovascular calcification.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: